EyePoint Pharmaceuticals, Inc.

NASDAQ:EYPT

Biotechnology

Healthcare
$2.99 +1.98%

+$0.26 today

Market cap
$250.69M
Beta
1.75
P/E (TTM)
-4.2
EPS (TTM)
-$3.16
52W Low $7.94High $19.11

Volume 2.75M

Average 0.95M

EYPT Pre-Tax Margin

Income before tax as a percentage of revenue.

EyePoint Pharmaceuticals, Inc.NASDAQ: EYPT

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin narrows to -12195.7%

Pre-tax margin was -12195.7% in Q1 FY2026, down 12010.9 pp from a year earlier. On a trailing-twelve-month basis it was -3563.6%, down 3301.9 pp year over year. Over 3 fiscal years it narrowed by 491.6 pp.

Context

  • Pre-tax margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-12195.7%-1321.0 pp QoQ
Last fiscal yearDec 2025
-738.5%-436.3 pp YoY
LTMMar 2026
-3563.6%-3301.9 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-12010.9 pp——
1 year-436.3 pp——
3 years-491.6 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-738.5%
Year-over-year change
-436.3pp

Pre-Tax Margin vs competitors

How EYPT compares with its peers on the latest reported figures

  • EYPT's LTM Mar 2026 pre-tax margin of -3563.6% is the 5th highest of the 7 companies compared; the peer median is -287.0%.
  • Its year-over-year change of -3301.9 pp is the lowest of 7, against a peer median of +273.9 pp.
  • Over three fiscal years its change of -491.6 pp compares with a peer median of +212.5 pp.
EYPT Competitors Peer median
Pre-Tax Margin for EYPT and competitors
Company Period LTM level YoY 3-year change
NRIXNurix Therapeutics, Inc.LTM Aug 202643.9% +335.5 pp+152.9 pp
SEPNSepterna, Inc.LTM Sep 2026-55.1% +212.4 pp—
TNGXTango Therapeutics, Inc.FY2025-162.8% +146.4 pp+272.1 pp
KURAKura Oncology, Inc.LTM Mar 2026-411.1% -146.9 pp—
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026-3563.6% -3301.9 pp-491.6 pp
PRMEPrime Medicine, Inc.LTM Mar 2026-4917.6% +338.4 pp—
PROKProKidney Corp.LTM Mar 2026-17599.3% +36668.3 pp—
KODKodiak Sciences Inc.FY2025— ——
BCAXBicara Therapeutics Inc. Common StockFY2025— ——
SVRASavara Inc.FY2025— ——
RZLTRezolute, Inc.FY2025— ——
Peer median (excluding EYPT) -287.0%+273.9 pp+212.5 pp

Competitors are the stored peer set for EYPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue36.94M41.4M46.02M43.27M31.37M
Cost of Revenue8.18M8.33M4.63M3.71M2.07M
Gross Profit28.76M33.08M41.39M39.56M29.31M
Gross Margin77.9%79.9%89.9%91.4%93.4%
Research & Development28.5M49.64M64.66M132.93M221.04M
Selling, General & Admin53.08M60.32M51.79M52.49M51.7M
Operating Expenses84.04M132.72M116.45M185.42M272.74M
Depreciation & Amortization2.77M2.45M464K1.54M2.31M
EBITDA(50.15M)(96.62M)(69M)(129.23M)(229.34M)
EBITDA Margin-135.8%-233.4%-149.9%-298.6%-731.1%
Operating Income(55.28M)(99.64M)(75.07M)(145.85M)(243.43M)
Operating Margin-149.6%-240.6%-163.1%-337.1%-776.0%
Interest Income292K2.13M6.95M15.09M11.75M
Interest Expense5.5M3.19M1.25M14K(33K)
Other Income / Expenses(3.14M)(2.62M)4.36M15.07M11.75M
Income Before Tax(58.42M)(102.25M)(70.71M)(130.78M)(231.68M)
Pre-Tax Margin-158.1%-247.0%-153.7%-302.2%-738.5%
Income Tax Expense0083K90K279K
Net Income(58.42M)(102.25M)(70.8M)(130.87M)(231.96M)
Net Margin-158.1%-247.0%-153.8%-302.4%-739.4%
EPS (Basic)(2.03)(2.74)(1.82)(2.32)(3.17)
EPS (Diluted)(2.03)(2.74)(1.82)(2.32)(3.17)
Weighted Avg Shares28.76M37.32M38.9M56.3M73.25M
Weighted Avg Shares (Diluted)28.76M37.32M38.9M56.3M73.25M

EyePoint Pharmaceuticals, Inc.

NASDAQ:EYPT

Intrinsic Alpha fair value

Locked

Current Price

$2.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.